Adocia: patent applications filed

(CercleFinance.com) - Adocia announces that it has filed patent applications for stable formulations of hormone combinations for the treatment of obesity and diabetes using its BioChaperone® platform.


Several families of hormones offer the potential for significant weight loss, starting with GLP-1 (e.g. semaglutide, tirzepatide...), but also including amylin analogues (e.g. cagrilintide, eloralintide, petrelintide...), which have the advantage of targeting fat mass while preserving muscle mass', says the group.

Future generations of obesity treatments, which analysts expect to reach a $100 billion market by 2030, will therefore combine these different mechanisms of action to achieve better weight loss in terms of both quantity and quality.

Thanks to its BioChaperone® platform for hormone combinations, Adocia has succeeded in obtaining several stable combinations. The resulting combinations can be manufactured and administered in the world's most widely used standard injection devices, autoinjectors and pens, for multiple or single use, as well as in standard vials with syringes.

Demand for anti-obesity products is growing exponentially, and this new application of our historic BioChaperone® platform puts us at the heart of the obesity field," says Olivier Soula, co-founder and CEO of Adocia.

The ease of use and manufacturing of our patented solution could meet the main challenge facing pharmaceutical companies: satisfying this rapidly expanding demand.


Copyright (c) 2024 CercleFinance.com. All rights reserved.